Comunicación corta
Bevacizumab intravítreo en el tratamiento de la neovascularización subretiniana secundaria a rotura coroidea
Use of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture
Leído
6189
Vecesse ha leído el artículo
2250
Total PDF
3939
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 7 | 7 |
| 2025 11 | 0 | 21 | 21 |
| 2025 10 | 0 | 16 | 16 |
| 2025 9 | 0 | 13 | 13 |
| 2025 8 | 0 | 32 | 32 |
| 2025 7 | 0 | 49 | 49 |
| 2025 6 | 0 | 19 | 19 |
| 2025 5 | 0 | 15 | 15 |
| 2025 4 | 0 | 25 | 25 |
| 2025 3 | 0 | 32 | 32 |
| 2025 2 | 0 | 23 | 23 |
| 2025 1 | 0 | 13 | 13 |
| 2024 12 | 0 | 21 | 21 |
| 2024 11 | 0 | 19 | 19 |
| 2024 10 | 0 | 25 | 25 |
| 2024 9 | 0 | 16 | 16 |
| 2024 8 | 0 | 10 | 10 |
| 2024 7 | 0 | 15 | 15 |
| 2024 6 | 0 | 16 | 16 |
| 2024 5 | 0 | 12 | 12 |
| 2024 4 | 0 | 23 | 23 |
| 2024 3 | 0 | 45 | 45 |
| 2024 2 | 0 | 42 | 42 |
| 2024 1 | 0 | 34 | 34 |
| 2023 12 | 0 | 45 | 45 |
| 2023 11 | 0 | 38 | 38 |
| 2023 10 | 0 | 49 | 49 |
| 2023 9 | 0 | 12 | 12 |
| 2023 8 | 0 | 28 | 28 |
| 2023 7 | 0 | 46 | 46 |
| 2023 6 | 0 | 30 | 30 |
| 2023 5 | 0 | 11 | 11 |
| 2023 4 | 0 | 16 | 16 |
| 2023 3 | 1 | 33 | 34 |
| 2023 2 | 0 | 19 | 19 |
| 2022 1 | 0 | 26 | 26 |
| 2022 12 | 0 | 39 | 39 |
| 2022 11 | 0 | 19 | 19 |
| 2022 10 | 0 | 5 | 5 |
| 2022 9 | 0 | 5 | 5 |
| 2022 8 | 0 | 9 | 9 |
| 2022 7 | 0 | 10 | 10 |
| 2022 6 | 0 | 2 | 2 |
| 2022 5 | 0 | 30 | 30 |
| 2022 4 | 0 | 14 | 14 |
| 2022 3 | 0 | 20 | 20 |
| 2022 2 | 0 | 17 | 17 |
| 2021 1 | 0 | 21 | 21 |
| 2021 12 | 0 | 21 | 21 |
| 2021 11 | 0 | 16 | 16 |
| 2021 10 | 0 | 21 | 21 |
| 2021 9 | 0 | 13 | 13 |
| 2021 8 | 0 | 11 | 11 |
| 2021 7 | 0 | 7 | 7 |
| 2021 6 | 0 | 7 | 7 |
| 2021 5 | 0 | 3 | 3 |
| 2021 4 | 0 | 5 | 5 |
| 2021 3 | 0 | 24 | 24 |
| 2021 2 | 0 | 14 | 14 |
| 2020 1 | 0 | 21 | 21 |
| 2020 12 | 0 | 27 | 27 |
| 2020 11 | 0 | 19 | 19 |
| 2020 10 | 0 | 18 | 18 |
| 2020 9 | 0 | 20 | 20 |
| 2020 8 | 0 | 28 | 28 |
| 2020 7 | 0 | 13 | 13 |
| 2020 6 | 0 | 15 | 15 |
| 2020 5 | 0 | 11 | 11 |
| 2020 4 | 0 | 5 | 5 |
| 2020 3 | 0 | 7 | 7 |
| 2020 2 | 0 | 13 | 13 |
| 2020 1 | 0 | 4 | 4 |
| 2019 12 | 0 | 32 | 32 |
| 2019 11 | 0 | 12 | 12 |
| 2019 10 | 0 | 18 | 18 |
| 2019 9 | 0 | 17 | 17 |
| 2019 8 | 0 | 9 | 9 |
| 2019 7 | 0 | 18 | 18 |
| 2019 6 | 1 | 37 | 38 |
| 2019 5 | 0 | 49 | 49 |
| 2019 4 | 0 | 63 | 63 |
| 2019 3 | 0 | 5 | 5 |
| 2019 2 | 0 | 22 | 22 |
| 2019 1 | 0 | 13 | 13 |
| 2018 12 | 0 | 15 | 15 |
| 2018 11 | 0 | 13 | 13 |
| 2018 10 | 0 | 32 | 32 |
| 2018 3 | 5 | 0 | 5 |
| 2018 2 | 16 | 2 | 18 |
| 2018 1 | 13 | 1 | 14 |
| 2017 12 | 25 | 6 | 31 |
| 2017 11 | 25 | 9 | 34 |
| 2017 10 | 23 | 4 | 27 |
| 2017 9 | 27 | 5 | 32 |
| 2017 8 | 36 | 17 | 53 |
| 2017 7 | 22 | 2 | 24 |
| 2017 6 | 38 | 28 | 66 |
| 2017 5 | 58 | 7 | 65 |
| 2017 4 | 44 | 2 | 46 |
| 2017 3 | 52 | 18 | 70 |
| 2017 2 | 106 | 13 | 119 |
| 2016 1 | 72 | 4 | 76 |
| 2016 12 | 97 | 10 | 107 |
| 2016 11 | 85 | 8 | 93 |
| 2016 10 | 82 | 3 | 85 |
| 2016 9 | 165 | 9 | 174 |
| 2016 8 | 73 | 6 | 79 |
| 2016 7 | 42 | 4 | 46 |
| 2016 6 | 40 | 17 | 57 |
| 2016 5 | 62 | 13 | 75 |
| 2016 4 | 54 | 6 | 60 |
| 2016 3 | 39 | 7 | 46 |
| 2016 2 | 60 | 17 | 77 |
| 2015 1 | 44 | 9 | 53 |
| 2015 12 | 46 | 12 | 58 |
| 2015 11 | 59 | 10 | 69 |
| 2015 10 | 47 | 12 | 59 |
| 2015 9 | 43 | 7 | 50 |
| 2015 8 | 89 | 9 | 98 |
| 2015 7 | 125 | 8 | 133 |
| 2015 6 | 39 | 4 | 43 |
| 2015 5 | 48 | 11 | 59 |
| 2015 4 | 33 | 18 | 51 |
| 2015 3 | 77 | 7 | 84 |
| 2015 2 | 75 | 10 | 85 |
| 2015 1 | 43 | 8 | 51 |
| 2014 12 | 94 | 11 | 105 |
| 2014 11 | 73 | 8 | 81 |
| 2014 10 | 85 | 8 | 93 |
| 2014 9 | 74 | 6 | 80 |
| 2014 8 | 63 | 12 | 75 |
| 2014 7 | 94 | 6 | 100 |
| 2014 6 | 67 | 5 | 72 |
| 2014 5 | 61 | 8 | 69 |
| 2014 4 | 43 | 7 | 50 |
| 2014 3 | 55 | 6 | 61 |
| 2014 2 | 43 | 7 | 50 |
| 2014 1 | 33 | 3 | 36 |
| 2013 12 | 57 | 5 | 62 |
| 2013 11 | 47 | 4 | 51 |
| 2013 10 | 62 | 8 | 70 |
| 2013 9 | 42 | 4 | 46 |
| 2013 8 | 36 | 9 | 45 |
| 2013 7 | 15 | 5 | 20 |
| 2011 11 | 764 | 0 | 764 |
Mostrar todo
